



## Ruth Demmer-Steingruber

study nurse

Medizinische Onkologie und Hämatologie · Dept. I

### Contact

Ruth Demmer-Steingruber  
Rorschacherstrasse 95  
9007 St. Gallen

T +41 71 494 6875  
Ruth.Demmer-Steingruber@kssg.ch

### Units

Medizinische Onkologie und Hämatologie

### Profile Function

study nurse

## Publications (4)

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. *Swiss Med Wkly* 2023; 153:40090.

Früh M, Gillessen Sommer S, Cerny T, Demmer-Steingruber R, D'Addario G. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. *Lung cancer (Amsterdam, Netherlands)* 2008; 62:344-50.

Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S, Thürlimann B, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. *The Oncologist* 2008; 13:337-46.

Strasser F, Cerny T, Von Moss R, Brändle M, Holst B, Kaufmann K, Tschöp M, Büche D, Thürlimann B, Maeder M, Lutz T, Demmer-Steingruber R. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. *BJC* 2008; 98:300-8.

## Projects (9)

**A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)**

*Clinical Studies - Nov 17, 2023 - Dec 31, 2028*

*Ongoing*

**Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien**

*Clinical Studies - Oct 1, 2021 - Feb 28, 2021*

*Automatically Closed*

**SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase II trial**

*Clinical Studies - Jun 24, 2021 - Jun 28, 2027*

*Ongoing*

**Swiss Soliris® and Ultomiris® Reimbursement Registry SSURR: An observational registry for capturing data of patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) who are treated with Soliris® (eculizumab) or Ultomiris® (ravulizumab)**

*Clinical Studies - Jan 1, 2021 - Dec 31, 2030*

*Ongoing*

**Prospective Observational international Registry of Patients with newly diagnosed peripheral T-Cell Lymphoma**

*Clinical Studies - Jan 1, 2019 - Dec 31, 2030*

*Ongoing*

**A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III**

*Clinical Studies - Oct 26, 2015 - Dec 31, 2030*

*Ongoing*

**Biomarkers Cancer Cachexia in Urin and Blood**

*Fundamental Research - Oct 14, 2012 - Dec 15, 2012*

*Aborted*

**Prospective evaluation of the predictive value of PET in patients with diffuse large B-cell-lymphoma under R-CHOP-14. A multicenter study**

*Clinical Studies - Jan 28, 2008 - Sep 28, 2011*

*Automatically Closed*

**Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial**

*Clinical Studies - Oct 25, 2006 - Oct 25, 2010*

*Completed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)